I met with my medical oncologist (MO) Thursday July 4, 2019 to talk about chemotherapy (aka systemic therapy).
Almost right off, my MO said that chemotherapy, for me, was entirely optional, which surprised me. I’ve always thought that the primary purpose of chemo was to implement a mechanism for killing off any cancer cells that might have migrated beyond the regions that surgery and radiation target.
But my MO corrected me; the primary purpose of chemotherapy, at least when applied to HPV related oropharyngeal cancer treatment, is to improve the efficacy of the radiation treatment. The platinum in Cisplatin (the drug that would be prescribed in my case) binds to the cancer cells and the platinum makes the cells more sensitive to the concurrent radiation therapy. Without the chemo, the radiation simply has a harder time killing the cells.
What I thought was the primary purpose of chemotherapy is instead the secondary purpose. And, what I also learned about HPV related base-of-tongue cancer, is that cancer cells very rarely migrate beyond the lymph nodes. Therefore, if the cancer is treated soon enough, as mine will be, that secondary “seek and destroy” purpose is almost unnecessary.
My MO also made me aware that, for HPV related oropharyngeal cancer, no randomized clinical tests have been conducted that show conclusively that the standard chemotherapy treatment actually has a significant impact on 5 year survivability. It’s possible that chemo would not actually help me.
A little background is required here. Please note that the following is what I remember my MO telling me; it may not be entirely accurate. I’ll provide updated information, and supporting citations, in future posts.
- Older survivability studies of patients with oropharyngeal cancer showed 5 year survivability rates of roughly 60%. In those studies, patients who received chemotherapy in addition to radiation therapy had a survivability rate about 8% higher than those patients who had radiation therapy only.
- But those studies did not differentiate patients who had smoking related cancer from those with HPV related.
- Studies show that people who live 5 years after treatment for the HPV related version of oropharyngeal cancer do not die of the same cancer; they are cured.
- Studies also show that the survivability rate for HPV related oropharyngeal cancer patients who receive both radiation and chemo therapies is around 80%
- But no studies have returned results yet that show that the chemotherapy that HPV related patients receive has the same 8% impact on survivability. Given that the HPV related cancer is a very different beast from the smoking related version, it’s very possible that the impact of chemotherapy is much lower than 8%. In fact, it’s possible that the chemotherapy could have a negative impact on survivability rates, because chemotherapy comes with side effects that can be very devastating.
- Nonetheless, the standard cancer treatment for oropharyngeal cancers, as recommended by ASCO (American Society Of Clinical Oncology) and ASTRO (American Society For Radiation Oncology), is radiation supplemented by Cisplatin chemotherapy. This will remain in effect until studies show that the chemotherapy is unnecessary. Studies have been started, but they have been running less than 5 years, so results aren’t in yet.
So I’ve got about 2 weeks to decide whether I want to have chemo. My MO is going to book a bed for me for the first day of treatment (see treatment plan below), and I can cancel it at the last minute (although giving a day’s notice would be better so they can give the bed to someone else).
Posts in the next couple of weeks will include my investigation into the pros and cons of chemo for HPV related oropharyngeal cancer. Those posts will include links to source materials.
Current Treatment Plan
- Chemo-radiation therapy will start Monday July 29, 2019
- I will be given radiation over a 7 week period. In that period I will have 35 daily treatments, Monday through Fridays.
- I will have 3 cycles of chemotherapy. Each cycle will comprise 1 daily treatment. Treatments will occur on Day 1 and Day 22. If my MO thinks it’s appropriate, I will have a treatment on Day 43.
- Cisplatin chemotherapy treatments take a long time, because it’s critical that the platinum be washed completely out of my vascular and renal system by the end of the treatment, and that my kidneys be checked before I leave the hospital. Therefore, just to make things a whole lot simpler, I will be checked in as an overnight patient for chemotherapy treatments.
- I have the right to go through the first cycle, determine that the side effects are too uncomfortable to continue, and discontinue treatment. Similarly, my MO could also decide to terminate chemotherapy if he decides that costs of continuing do not warrant the hoped-for benefits.
- My MO frequently suspends chemo treatments after the 2nd cycle
Alternative Treatment Plan
If I decline chemotherapy, my radiation oncologist would put me on an accelerated treatment plan. I would still receive my total dosages (70 Gy to the primary site and 56 Gy to elective sites), but over just 6 weeks. On one day of the week I would receive 2 doses instead of 1.
This alternative radiation plan is given to accommodate the lack of chemo. As I noted above, the primary purpose of chemo is to accelerate the death of cancer cells by making them more sensitive to concurrent radiation therapy. The doubling up of doses is intended to make up for the fact that the cancer will be less sensitive.
Other Systemic Therapies
The chemotherapy that my MO has in mind for me is known in BC as “HNLAPRT” (Head and Neck Locally Advanced Platinum Radiation Therapy). The BC Cancer Agency’s patient handout for this therapy talks about the following.
- what Cisplatin is
- its intended benefits
- the HNLAPTR treatment summary
- treatment protocol (i.e. cycle details)
- chemotherapy side effects and management
- radiation side effects and management
Other systemic therapies available for use with radiation therapy include the following. Patient handouts and protocol summaries for each of these can be found at the BC Cancer Agency’s Head & Neck Chemotherapy Protocols page.
- HNLAALTPRT (Head and Neck Locally Advanced ALTernate Platinum Radiation Therapy)
- The treatment cycle changes so that the patient receives smaller but more frequent doses
- HNLACETRT (Head and Neck Locally Advanced CETuximab Radiation Therapy )
- Cetuximab is used when Cisplatin cannot be used, for example when the patient’s renal function is already impaired, or already has tinnitus or some hearing loss
- HNLACNFRT (Head and Neck Locally Advanced CArboplatin and Fluorouracil Radiation Therapy )
- This treatment is very hard on the body and is very rarely used anymore
Cisplatin Side Effects
- nausea, often with vomiting
- The MO would attempt to reduce nausea by having me take anti-nausea medication prior to taking the Cisplatin. The anti-nausea drugs themselves have side effects.
- diarrhea
- mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract
- damage to bone marrow leading to
- reduction in number of red blood cells resulting in fatigue
- reduction in number of white blood cells resulting in reduced ability to fight infection
- reduction in number of platelets resulting in increased bruising
- kidney damage resulting from platinum damage to cells
- hearing loss
- hair loss from the Cisplatin is rare
- tinnitus is the perception of noise or ringing in the ears
- neuropathy is the loss of feeling in fingers, hands, and feet, and can sometimes become permanent
- weight loss that compromises health
- increased susceptibility to auto-immune diseases
Why I am a good candidate for Cisplatin treatment
My ECOG performance status is 0. That means that I am “Fully active, able to carry on all pre-disease performance without restriction”. Therefore, I should be able to handle the additional burdens placed on my body by the chemo supplement better than someone at higher ECOG ratings.
The Eastern Cooperative Oncology Group (ECOG) is one of the largest clinical cancer research organizations in the United States and conducts clinical trials in all types of adult cancers.
The ECOG performance status is a scale used to assess how a patient’s disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis
Radiopaedia
Weight loss issues
My MO tells me that the dietitian that I’ve been assigned to is a person who is very determined to maintain my weight at acceptable levels, and will be on the MO’s case if my weight drops more than 10% of my baseline weight. From reading the HNLAPRT protocol document, I see that, when the 10% is hit, either the patient gets a feeding tube and the chemo dose drops by 25%, or chemo must be discontinued.
I asked which of my many weights is deemed the “baseline”, because, knowing that weight loss is an issue, I’ve been bulking up. I was 169 lbs when had my open biopsy on May 22, and my desire is to have that treated as my baseline; on my 6’1″ frame I’ll definitely be skinny if I drop to 152 lbs, but I won’t be on death’s door. According to my MO though, the standard baseline is defined as the weight I have when treatment commences, which I’m hoping will be around 185 lbs.
Thinking about this more, I’m starting to think I may be really wrong in thinking that allowing myself to drop 18% from 185 to 152 would be OK. That 10% figure indicates that the treatment is having a very significant effect on my body, and that the treatment needs to be amended some way to ameliorate the side effects.
My thoughts
I’m seriously considering not going with the chemo. I really want to minimize the side effects of my treatment, and some of the chemo side effects sound pretty severe.
I might also say, “Let’s try one cycle, and see how it goes.” But I don’t know how the radiation oncologist would like that; would he want, or not want, to accelerate his treatment?
I think I’ll chat this over with other members of “my” team (dietitian, radiation oncologist, speech language pathologist, and general practitioner in oncology) to get their thoughts.